Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT00002831

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia

A Phase I/II Study of High-Dose Deoxyazacytidine, Busulfan, and Cyclophosphamide With Allogeneic Stem Cell Transplantation for Hematologic Malignancies

Sponsor: M.D. Anderson Cancer Center

Conditions Leukemia

Interventions Allogeneic Bone Marrow Transplantation Busulfan Cyclophosphamide Cyclosporine Decitabine (DAC) Filgrastim Methotrexate Methylprednisolone Peripheral Blood Stem Cell Transplantation Tacrolimus

Updated 6 times since 2017 Last updated: Oct 24, 2018 Started: Aug 1, 1995 Primary completion: Dec 31, 2002 Completion: Dec 31, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00002831, this PHASE1/PHASE2 trial focuses on Leukemia and remains completed. Sponsored by M.D. Anderson Cancer Center, it has been updated 6 times since 1995, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Nov 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Nov 2018 [monthly]

Completed PHASE1_PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

First recorded

Aug 1995

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States